Latest Attention-deficit hyperactivity disorder management Stories
--Children's Hospital of Philadelphia Research Suggests that Interventions at the Glutamate Transmission Level Might Treat Disorder-- PHILADELPHIA, Dec. 4, 2011 /PRNewswire-USNewswire/ -- Pediatric researchers analyzing genetic influences in attention-deficit/hyperactivity disorder (ADHD) have found alterations in specific genes involved in important brain signaling pathways. The study raises the possibility that drugs acting on those pathways might offer a new treatment option for...
PHILADELPHIA, Dec. 1, 2011 /PRNewswire/ -- Shire plc, the global specialty biopharmaceutical company, responds to questions about reports of a supply shortage of ADDERALL® (mixed salts of a single-entity amphetamine product) Tablets, CII. ADDERALL® is an immediate release formulation and is sometimes referred to as "ADDERALL IR." While Shire is aware of the reports of the supply shortage, Shire cannot provide additional information because Shire does not own, manufacture or...
Up to 5% of Adults Have Attention-Deficit/Hyperactivity Disorder, Finds JAOA - The Journal of the American Osteopathic Association Clinical Review CHICAGO, Nov. 21, 2011 /PRNewswire-USNewswire/ -- Often thought of as a childhood affliction, more than 50% of children with attention-deficit/hyperactivity disorder (ADHD) will carry the disorder over into adulthood, according to a review of adult ADHD studies that appeared in a recent issue of JAOA - The Journal of the American...
NYON, Switzerland and PHILADELPHIA, November 18, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has entered into an agreement with Shionogi & Co. Ltd. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan. Shionogi will pay a one time fee and share costs with Shire in exchange for rights to jointly co-develop and...
According to new research, over one-in-four women take medication to treat a mental health condition. The report by Medco Health Solutions found that women of all ages take more mental health medications than males, with antidepressants being the most commonly used. Anxiety treatments are also widely used by women and at almost twice the rate of men, and the greatest age group who uses these drugs were women between 45 and 65 years of age. The number of women on ADHD drugs was 2.5...
ROCKVILLE, Md., Oct. 24, 2011 /PRNewswire-USNewswire/ -- Formal training in parenting strategies is a low-risk, effective method for improving behavior in preschool-age children at risk for developing attention deficit hyperactivity disorder (ADHD), while there is less evidence supporting the use of medications for children younger than 6 years old, according to a new report from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ). The report...
BASINGSTOKE, England, October 21, 2011 /PRNewswire/ -- Success of pivotal, phase III trial marks long-acting, prodrug stimulant LDX as potential new treatment option for ADHD in Europe For international medical media only Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged...
New guidelines from the American Academy of Pediatrics (AAP) offer new information on helping doctors diagnose and treat children with Attention-Deficit/Hyperactivity Disorder (ADHD). The guidelines describe the special considerations involved in diagnosing and treating children and adolescents. The new guidelines for children from ages 4 to 18 also help children with hyperactive/impulsive behaviors that do not meet the full diagnostic criteria for ADHD. "Treating children at a young...
(Ivanhoe Newswire) -- Updated guidelines from the American Academy of Pediatrics (AAP) offer new information on diagnosing and treating Attention-Deficit/Hyperactivity Disorder (ADHD) in younger children and in adolescents. ADHD is the most common neurobehavioral disorder in about 8 percent of children. Emerging evidence makes it possible to diagnose and manage ADHD in children from ages 4 to 18 (the previous AAP guidelines, from 2000 and 2001, covered children ages 6 to 12). The new...
The Better Hearing Institute is highlighting the relationship between Attention Deficit/Hyperactivity Disorder (ADHD) and hearing loss in recognition of ADHD Awareness Week, which runs from October 16 through 22. BHI is underscoring the importance of hearing checks as part of the ADHD diagnosis process. And in an effort to ensure that the needs of children with ADHD are fully met, BHI also is encouraging appropriate treatment by a hearing health professional when hearing loss and/or other...
